Kim Tae Hyun, Lee Keun Seok, Sim Sung Hoon, Kim Yeon-Joo, Kim Dae Yong, Chae Heejung, Lee Eun-Gyeong, Han Jai Hong, Jung So Youn, Lee Seeyoun, Kang Han Sung, Lee Eun Sook
Center for Proton Therapy, National Cancer Center, Goyang, South Korea.
Center for Breast Cancer, National Cancer Center, Goyang, South Korea.
Front Oncol. 2021 Nov 3;11:783327. doi: 10.3389/fonc.2021.783327. eCollection 2021.
Few studies of proton beam therapy (PBT) for patients with liver metastasis from breast cancer (LMBC) are available to date. The aim of the present study was to evaluate the clinical effectiveness of PBT for patients with LMBC.
Seventeen patients with LMBC treated with PBT were included in this study. The median prescribed dose of PBT was 66 GyE (range, 60-80) in 10 fractions, 5 times a week. In patients with LMBC receiving PBT, freedom from local progression (FFLP), progression-free survival (PFS), and overall survival (OS) rates were assessed.
The median follow-up time was 34.2 months (range, 11.5-56.1). The median FFLP time was not yet reached, and the 3-year FFLP rates were 94.1% (95% confidence interval [CI], 82.9-105.3). The median times of PFS and OS were 7.9 months (95% CI, 5.3-10.5) and 39.3 months (95% CI, 33.2-51.9), respectively, and the 3-year PFS and OS rates were 19.6% (95% CI, -1.8-41.0) and 71.7% (95% CI, 46.8-96.6), respectively. Grade 3 or higher adverse events were not observed.
PBT for patients with LMBC showed promising FFLP and OS with safe toxicity profiles. These findings suggest that PBT can be considered a local treatment option in patients with LMBC.
迄今为止，关于质子束治疗（PBT）用于乳腺癌肝转移（LMBC）患者的研究较少。本研究的目的是评估PBT对LMBC患者的临床疗效。
本研究纳入了17例接受PBT治疗的LMBC患者。PBT的中位处方剂量为66 GyE（范围60 - 80），分10次给予，每周5次。对接受PBT的LMBC患者评估局部无进展生存期（FFLP）、无进展生存期（PFS）和总生存期（OS）率。
中位随访时间为34.2个月（范围11.5 - 56.1）。FFLP时间中位数尚未达到，3年FFLP率为94.1%（95%置信区间[CI]，82.9 - 105.3）。PFS和OS的中位时间分别为7.9个月（95% CI，5.3 - 10.5）和39.3个月（95% CI，33.2 - 51.9），3年PFS和OS率分别为19.6%（95% CI， - 1.8 - 41.0）和71.7%（95% CI，46.8 - 96.6）。未观察到3级或更高等级的不良事件。
PBT治疗LMBC患者显示出有前景的FFLP和OS，且毒性特征安全。这些发现表明PBT可被视为LMBC患者的一种局部治疗选择。
